TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES
Tesi di Dottorato
Data di Pubblicazione:
2023
Citazione:
TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES / L. Bisbal Lopez ; tutor: A. Dal Corso, C. Gennari ; coordinatore: D. Passarella. Università degli Studi di Milano, 2023 Dec 01. 35. ciclo, Anno Accademico 2022.
Abstract:
Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification
Tipologia IRIS:
Tesi di dottorato
Keywords:
Immune-Stimulating Antibody Conjugates; Toll-Like Receptors; Resiquimod; Antibody Engineering; Prodrugs; Self-Immolative Spacers
Elenco autori:
L. BISBAL LOPEZ
Link alla scheda completa: